Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4686 | questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D019052 | Depression, Postpartum NIH | 0.33 |
| D003863 | Depression, NIH | 0.11 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Postpartum depression (PPD) already affects up to 1 in 5 women and left untreated costs $150,000 per case over the lifespan. Under normal conditions, just 10% of women with PPD get evidence-based treatment, a situation that has worsened substantially during COVID-19. The purpose of this study is to a assess if self-referred, online adaptation of a 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop for PPD delivered up to 30 women at a time can lead to reductions in PPD, if the workshops are cost-effective, and to assess workshop impact on common complications of PPD (anxiety, partner relationship discord, problems with mother-infant attachment). 334 women will be randomized to receive either immediate treatment or treatment 12 weeks later (waitlist control). Study measures will be collected at baseline (immediately before treatment workshop) and 12 weeks later (immediately before wait list control workshop).
Description: The gold standard measure of PPD in clinical practice/research. A change of 4 points is recognized as a clinically meaningful/significant improvement.
Measure: Edinburgh Postnatal Depression Scale (EPDS) Time: Differences between experimental and control groups from T1 (baseline) to T2 (12 weeks) will be compared.Description: Healthcare resource utilization data will be collected using a questionnaire based on the Canadian Community Health Survey and the Service Use and Resources Form adapted for the postpartum period and used in previous PPD research. Costs will be calculated using provincial or other standard billing rates.
Measure: Cost-effectiveness: Costs of service Time: Resources consumed over the 12-week trial period from the perspective of public healthcare payer will be measured.Description: The EQ-5D-5L, a utility-based health-related quality of life instrument will be used. Its validity in measuring the impact of depression is established. Its Canadian scoring algorithm will be used. For each participant, a QALY will be calculated by multiplying the health utility for the matching time period (i.e., the area under the curve approach).
Measure: Cost-effectiveness: Quality-Adjusted Life Year (QALY) Time: QALYs will be measured over the 12-week trial period.Description: A 7-item self-report scale of symptoms of generalized anxiety disorder, the most common PPD comorbidity.
Measure: Generalized Anxiety Disorder-7 (GAD-7) Time: 12 weeksDescription: 25-item maternal-report scale of mother-infant attachment.
Measure: Postpartum Bonding Questionnaire Time: 12 weeksDescription: The SPS is a 24-item self-report measures of the degree to which an individual's social relationships provide support.
Measure: Social Provisions Scale Time: 12 weeksDescription: A 37-item meausure of infant behavior and temperament.
Measure: Infant Behavior Questionnaire - Revised (Very Short Form) Time: 12 weeksDescription: Differences between experimental and control groups from T1 (baseline) to T2 (12 weeks) will be compared.
Measure: Beck Depression Inventory-II (BDI-II) Time: 12 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports